The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


What constitutes sufficient clinical evidence for stents? SpotLITE on the evaluation of novel coronary devices

EuroIntervention 2019;15:e1035-e1037. DOI: 10.4244/EIJV15I12A194

1. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; 2. Cardio Center, Humanitas Clinical and Research Center IRCCS, Rozzano, Milan, Italy; 3. Department of Cardiology, Mater Private Hospital, Dublin, Ireland; 4. School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

Since the advent of percutaneous coronary intervention (PCI) in the late 1970s, successive technological innovations have been essential to the observed improvement in patient outcomes with this technique. Nowadays, contemporary drug-eluting stents (DES) are characterised by excellent efficacy and safety profiles during long-term follow-up1. Specific design developments have contributed to the high performance, including the use of newer metallic alloys permitting thinner strut dimensions, biocompatible polymer coatings, and more effective antiproliferative agents. However, suboptimal performance is observed and remains a challenge in certain high-risk subgroups. For example, an unmet need may be said to exist for new devices in ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Transtricuspid gradient after percutaneous edge-to-edge tricuspid valve repair: are we looking at the right side?